Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)
September 30, 2022 11:51 AM EDTUpdated April 20, 10:02 AM
FDA+

Ad­vo­cates, ex­perts cry foul over Amy­lyx's new ALS drug, cit­ing is­sues with price, PhI­II com­mit­ment

Max Gelman

Senior Editor

Not 24 hours af­ter earn­ing the first ALS drug ap­proval in five years, Amy­lyx Phar­ma­ceu­ti­cals’ Re­lyvrio is al­ready draw­ing scruti­ny. And it’s com­ing from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times